Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
For patients with resectable early-stage gastric and gastroesophageal junction cancers
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Subscribe To Our Newsletter & Stay Updated
